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Abstract
Objective: To assess the reliability of treatment recommendations based on network meta-analysis (NMA).
Study Design and Setting: We consider evidence in an NMA to be potentially biased. Taking each pairwise contrast in turn, we use a
structured series of threshold analyses to ask: (1) ‘‘How large would the bias in this evidence base have to be before it changed our deci-
sion?’’ and (2) ‘‘If the decision changed, what is the new recommendation?’’ We illustrate the method via two NMAs in which a Grading of
Recommendations Assessment, Development and Evaluation (GRADE) assessment for NMAs has been implemented: weight loss and
osteoporosis.
Results: Four of the weight-loss NMA estimates were assessed as ‘‘low’’ and six as ‘‘moderate’’ quality by GRADE; for osteoporosis,
six were ‘‘low,’’ nine were ‘‘moderate,’’ and 1 was ‘‘high.’’ The threshold analysis suggests plausible bias in 3 of 10 estimates in the weight-
loss network could have changed the treatment recommendation. For osteoporosis, plausible bias in 6 of 16 estimates could change the
recommendation. There was no relation between plausible bias changing a treatment recommendation and the original GRADE
assessments.
Conclusions: Reliability judgments on individual NMA contrasts do not help decision makers understand whether a treatment recom-
mendation is reliable. Threshold analysis reveals whether the final recommendation is robust against plausible degrees of bias in the
data.  2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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1. Introduction
Network meta-analysis (NMA) is routinely used by
health reimbursement agencies to evaluate the clinical
and cost-effectiveness of multiple competing interventions
[1,2]. Because the statistical principles of the method are
well documented [3,4], attention has recently focused on
assessing the reliability of conclusions from an NMA.
Two approaches for NMA have been proposed, both based
on the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) method for rating the con-
fidence in an estimate from pairwise meta-analysis [5].
Briefly, a GRADE assessment rates the quality of evidence
informing a pairwise meta-analysis as high, moderate, low,
or very low [6] across five domainsdstudy limitations,
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What is new?
 GRADE has previously been used to assess the reli-
ability of evidence from a network meta-analysis
Quality judgements made for individual NMA con-
trasts do not help decision makers determine whether
a given treatment recommendation is reliable.
 Health care evaluation and technology assessment
organisations need to know whether potential flaws
in the evidence base would change the treatment
recommendation.
 A threshold analysis is used to explore how robust
treatment recommendations are to plausible de-
grees of bias in the data.
imprecision, indirectness, inconsistency (in the GRADE
framework this is equivalent to heterogeneity), and publica-
tion bias. Evidence from randomized controlled trials starts
as high confidence and can be downgraded by a maximum
of two levels per domain. A summative judgment of quality
is formed across all five domains [7] and interpreted as
summarized in Table 1.
The GRADE working group [8] has extended this
approach to NMA (GRADE NMA). Their first step is to rate
confidence in each direct, pairwise summary, as mentioned
previously, and the second is to generate an assessment for
each of the ‘‘indirect’’ estimates (based on the assessment
of the direct estimates informing it). For manageability,
GRADE NMA focusses on ‘‘first order’’ indirect loops only,
that is, triangular loops of three treatments AeBeC. To eval-
uate confidence in the effect estimates generated by the NMA,
GRADE suggests using the higher of the two judgments from
the direct and indirect evidence; for example, if the direct B
vs. C evidence is judged as ‘‘moderate’’ and the indirect B
vs. C as ‘‘low’’ quality evidence, the NMA judgment for
the B vs. C contrast would be ‘‘moderate.’’ The process gen-
erates a set of unrelated assessments of the quality of evidence
on each of the pairwise contrasts, but, critically, not on the
reliability of the treatment recommendation itself.
A second proposal [9] delivers an assessment of both the
confidence in the pairwise contrasts and the confidence in
the treatment rankings generated by the entire network of ev-
idence. Underlying this approach is the fact that each treat-
ment effect estimate from an NMA is essentially a weighted
average of all available direct estimates [10,11]. These
weights are used to calculate the percentage contribution
of each direct estimate to each NMA estimate and, crucially,
to the network as a whole [12,13]. Then, the confidence
ascribed to a treatment contrast is formed by combining
the evaluation of the available direct comparisons with their
relative contribution in the estimation. For pairwise esti-
mates generated from simple networks, we expect both
methods would produce similar judgments of quality.
An assessment of the quality of evidence is important;
however, health care evaluation agencies also need to know
whether potential problems in the evidence are serious
enough that they should reconsider a treatment recommen-
dation made on the basis of an NMA. Assuming the decision
maker is interested in selecting the treatment with the high-
est expected efficacy, the key question regarding the quality
of the NMA evidence takes the form: ‘‘given potential im-
perfections in the evidence, how reliable is the treatment
recommendation based on the NMA?’’ In this article, we
contrast the GRADE NMA approach with a structured series
of threshold analyses that explore the robustness of a treat-
ment recommendation to potential bias in the evidence base.
We use GRADE NMA because, to date, it is the more widely
implemented of the two proposals. Our starting point is the
same as GRADE, namely a set of summary estimates of
each of the pairwise comparisons on which there are data,
and we introduce two illustrative networks to which the
GRADE NMA approach has been applied. Next, we set
out the principles of a threshold analysis for assessing the
reliability of NMA results and apply it to the example data
Table 1. Levels of quality assigned by the GRADE approach to assessing the confidence that can be assigned to the pooled effect estimate from a
pairwise meta-analysis
Quality level Current definition Previous definition
High We are very confident that the true effect lies close to
that of the estimate of the effect
Further research is very unlikely to change our
confidence in the estimate of effect
Moderate We are moderately confident in the effect estimate: The
true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially
different
Further research is likely to have an important impact
on our confidence in the estimate of effect and may
change the estimate
Low Our confidence in the effect estimate is limited: The
true effect may be substantially different from the
estimate of the effect
Further research is very likely to have an important
impact on our confidence in the estimate of effect
and is likely to change the estimate
Very low We have very little confidence in the effect estimate:
The true effect is likely to be substantially different
from the estimate of effect
Any estimate of effect is very uncertain
Abbreviation: GRADE, Grading of Recommendations Assessment, Development and Evaluation.
‘‘Current definition’’ adopted in 2011 series of articles published in Journal of Clinical Epidemiology. ‘‘Previous definition’’ used in 2008 BMJ
series of GRADE articles (see references 5e7 for further information).
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sets. In Section 4, we suggest alternative starting points and
other extensions of the approach; we also discuss general
properties of the GRADE NMA approach which may cause
it to give misleading results for the decision maker.
2. Method
2.1. Illustrative examples
The illustrative examples used here are two published
NMAs which have applied the assessment method pro-
posed by the GRADE working group (GRADE NMA).
Data are reported as pairwise summary estimates of treat-
ment effect (Tables 2 and 3), and so here we assume effect
estimates have arisen from two-arm trials. We consider the
impact of this assumption in a sensitivity analysis. The data
are described as follows:
2.1.1. Branded weight-loss programs
Johnston et al. [14] analyzed branded weight-loss pro-
grams vs. another program, usual care, or no intervention.
Five classes were considered: No diet, The Lifestyle, Exer-
cise, Attitudes and Nutrition diet (LEARN), Moderate mac-
ronutrients (Moderate), Low carbohydrate (Low Carb), and
Low Fat diets. Within these classes, there were total of 12
branded diets, plus LEARN and No diet. It is a fully con-
nected network as shown in Fig. 1A, such that direct evi-
dence was available for all 10 possible comparisons at the
class level. Johnston reports mean weight loss (kg) at
Table 2. Weight-loss programs: summary results (difference in mean weight loss [kg]) and GRADE assessment of the direct and indirect analyses
and NMAs
Comparison (active
vs. control)
Mean difference (95% CI) Quality of evidence (GRADE)
Direct Indirect Network Direct Indirect Network
LEARN vs. No diet 3.67 (3.88, 11.21) 3.63 (0.36, 6.91) 5.16 (2.68, 7.63) Low Low Low
Moderate vs. No diet 4.84 (2.82, 6.86) 4.69 (1.73, 7.75) 5.70 (4.14, 7.35) Low Low Moderate
Low Carb vs. No diet 9.34 (7.31, 11.37) 5.16 (2.25, 8.18) 7.25 (5.33, 9.25) Low Moderate Moderate
Low fat vs. No diet 5.97 (2.01, 9.92) 6.15 (2.96, 9.40) 7.27 (5.26, 9.34) Moderate Moderate Moderate
Moderate vs. LEARN 0.21 (4.64, 5.05) 0.94 (1.74, 3.66) 0.55 (1.71, 2.87) Low Low Low
Low Carb vs. LEARN 1.23 (1.22, 3.67) 2.48 (0.19, 5.19) 2.10 (0.20, 4.47) Low Low Low
Low fat vs. LEARN 4.00 (0.21, 8.21) 2.64 (0.02, 5.33) 2.12 (0.33, 4.59) Low Low Low
Low Carb vs. Moderate 1.07 (0.16, 1.97) 2.05 (0.92, 4.96) 1.55 (0.13, 2.95) Moderate Low Moderate
Low fat vs. Moderate 1.84 (0.96, 2.72) 1.38 (0.75, 3.51) 1.56 (0.17, 3.30) Moderate Low Moderate
Low fat vs. Low Carb 0.33 (0.86, 1.52) 0.39 (1.92, 2.70) 0.02 (1.78, 1.79) Low Moderate Moderate
Abbreviations: GRADE, Grading of Recommendations Assessment, Development and Evaluation; NMAs, network meta-analyses; CI, confidence
interval.
Adapted from [14]. Direct estimates were reported by original authors as being based on Der Simonian and Laird [37]; network estimates were
reported as based on hierarchical Bayesian network meta-regression [38] ‘‘accounting for exercise and behavioral support’’ [14].
Table 3. Osteoporotic hip fractures GRADE NMA assessment of the direct and indirect analyses and NMAs
Comparison (active vs. control)
Odds ratio (95% CI) Quality of evidence (GRADE)
Direct Indirect Network Direct Indirect Network
Raloxifene vs. placebo 0.84 (0.63 to 1.13) 0.96 (0.53 to 1.78) 0.87 (0.63 to 1.22) Moderate Low Moderate
Risedronate vs. placebo 0.17 (0.05 to 0.59) 0.54 (0.36 to 0.75) 0.48 (0.31 to 0.66) Low Low Low
Vitamin D vs. placebo 1.25 (0.82 to 1.89) 1.08 (0.61 to 1.91) 1.13 (0.94 to 1.34) Low Low Low
Vitamin D þ calcium vs. placebo 0.83 (0.73 to 0.96) 0.54 (0.29 to 0.94) 0.81 (0.68 to 0.96) Moderate Low Moderate
Vitamin D þ calcium vs. teriparatide 2.00 (0.50 to 8.33) d 1.92 (0.45 to 8.42) Low d Low
Vitamin D þ calcium vs. denosumab 1.67 (1.02 to 2.70) d 1.64 (0.97 to 2.87) Moderate d Moderate
Alendronate vs. raloxifene 0.49 (0.04 to 5.45) 0.53 (0.30 to 0.90) 0.51 (0.29 to 0.87) Low Moderate Moderate
Vitamin D þ calcium vs. raloxifene 0.88 (0.51 to 1.54) 0.96 (0.63 to 1.49) 0.94 (0.66 to 1.31) Moderate Low Moderate
Vitamin D þ calcium vs. zoledronate 1.64 (1.16 to 2.17) d 1.63 (1.16 to 2.30) High d High
Vitamin D þ calcium vs. risedronate 1.92 (0.84 to 4.35) 5.88 (1.79 to 25.00) 1.69 (1.27 to 2.54) Very low Low Low
Vitamin D þ calcium vs. ibandronate 1.72 (0.76 to 3.85) d 1.69 (0.69 to 3.84) Low d Low
Vitamin D vs. alendronate 3.70 (1.20 to 11.11) 2.38 (1.49 to 3.85) 2.54 (1.63 to 4.16) Moderate Moderate Moderate
Vitamin D þ calcium vs. alendronate 1.59 (1.03 to 2.44) 2.78 (1.14 to 8.33) 1.82 (1.24 to 2.90) Moderate Moderate Moderate
Calcium vs. alendronate 4.55 (0.47 to 50.00) 2.56 (1.54 to 4.35) 2.56 (1.57 to 4.34) Very low Moderate Moderate
Vitamin D þ calcium vs. vitamin D 1.03 (0.68 to 1.54) 0.65 (0.48 to 0.85) 0.72 (0.57 to 0.91) Low Low Low
Calcium vs. calcium þ vitamin D 1.21 (0.89 to 1.66) 3.43 (0.26 to 160.4) 1.40 (1.03 to 1.95) Low Very low Moderate
Abbreviations: GRADE, Grading of Recommendations Assessment, Development and Evaluation; NMAs, network meta-analyses; CI, confidence
interval.
Estimates are odds ratios (ORs), where OR !1 favors active treatment.
Adapted from [8]. Only comparisons for which direct data were available are shown here. Original authors report direct estimates as based on
random-effects models estimated by Comprehensive Meta-analysis version 2 [39]. Network estimates were reported [15] as being based on
Bayesian random-effects NMA using methods of Lu and Ades [3].
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12 months based on 25 trials. The data available are sum-
marized in Table 2 in summary form for 12-month weight
loss and the direct and indirect analyses and NMAs along
with GRADE assessments.
2.1.2. Drug treatments for osteoporosis
To illustrate the GRADE NMA approach, Puhan et al.
[8] used an NMA of 10 drug treatments and placebo to pre-
vent fractures in individuals with or at risk of osteoporosis
[15]. The active treatments were alendronate, risedronate,
zoledronate, ibandronate, teriparatide, raloxifene, denosu-
mab, and calcium and/or vitamin D. Direct data, in the form
of odds ratios (OR) and 95% confidence intervals (95%
confidence interval), are available for 16 of the 55 possible
pairwise comparisons. From Fig. 1B, we note the bulk of
treatment comparisons are via placebo and vitamin D plus
calcium. Four treatments are only compared to vitamin D
plus calcium in single trials and are connected to the
network as ‘‘spurs.’’ The data available are summarized
in Table 3 in summary form for the outcome osteoporotic
hip fracture, and the direct, indirect, and NMA analyses
are shown along with the GRADE assessments.
2.2. Statistical analysis
2.2.1. Base-case analysis
GRADE NMA assessments are performed on the sum-
mary pairwise estimates. Thus, our base-case analysis takes
the form of a ‘‘two-stage’’ NMA [10,16] where data are in
the form of a set of summary estimates DXY comparing
treatments X and Y with expectation dXY and variance
s2XY . The contribution to the likelihood is given by
DXY|NðdXY ; s
2
XYÞ. From this ‘‘first-stage’’ input data set,
we construct an NMA by expressing the expectations of
the pairwise contrasts in terms of basic parameters
dXY5d1Y  d1Y ; X; Ys1 which are given vague priors
d1j|Nð0; 100
2Þ; j52:::NT ; d1150, where NT is the
number of treatments. These are the effects of treatments
X and Y relative to the chosen reference treatment, which
is No diet in the weight-loss network and placebo in the
osteoporosis network.
In both networks, the direct pairwise estimates used as
inputs were based on pooled summaries from random-
effects meta-analyses, as set out in the original publications
[14,15], although fixed-effect estimates were used for con-
trasts informed by a single trial. Global goodness of fit of
the NMA can be assessed by the posterior mean of the stan-
dardized residual deviance, which will be close to the num-
ber of pairwise contrasts in a good-fitting model [17].
According to a decision-making approach, the base case
recommended T is the treatment with the highest expected
treatment effect (or lowest depending on the context):
T  5ArgMaxTEd½d1T  ð1Þ
where the vector d represents the relative effects
d1j; j52:::NT . The OpenBUGS (http://www.openbugs.
net/w/GNU-License) code for this base-case analysis ap-
pears in the Supplementary Materials (Section 1)/
Appendix, along with the illustrative data sets.
2.2.2. Threshold analysis
We compare the GRADE NMA analysis and a threshold
analysis based on the two-stage NMA. The threshold analysis
examines each of the summary ‘‘direct’’ pairwise estimates in
turn and asks the following question: suppose that this sum-
mary estimate was biased, how large would the bias have to
be before it led to a change in the treatment recommendation?
The theory underlying this derives from the bias models
familiar in both general epidemiology [18] and in bias-
adjusted synthesis of RCTs [19e22]. Briefly, if the available
evidence DXY is considered to be biased, then instead of in-
forming the target parameter dXY , via DXY|NðdXY ; s
2
XYÞ, it in-
forms a biased parameter DXY|NðdXY þ b; s
2
XYÞ. It is
therefore only possible to recover an estimate of dXY from
the data available to the extent that we know the distribution
of the bias, b|NðB;s2BÞ. A simple approach, then, would be
to carry out a synthesis in which the original data DXY are re-
placed by a ‘‘bias-adjusted’’ version, approximately:
Learn
Low carb
Low fat
Moderate
No diet
Placebo
Teriparatide
Denosumab
Raloxifene
Zoledronate
Risedronate
Ibandronate
Alendronate
VitaminD VitaminD+Calcium
Calcium
A B
Fig. 1. (A) Network of comparisons as described by Johnston [14]. Edge thickness is proportional to the number of trials contributing to that pair-
wise contrast. Treatment nodes are not weighted. (B) Osteoporosis network adapted from [8]. Edge thickness is proportional to the number of trials
contributing to that pairwise contrast. Treatment nodes are proportional to number of participants.
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D
Adj
XY5ðDXY  bÞ|NðdXY  B; s
2
XY þ s
2
BÞ, as proposed by
Turner et al. [21]. Here we assume that the bias is known,
with no uncertainty (s2B50). As noted in Section 4, this rep-
resents a conservative analysis in that allowing for uncer-
tainty would mean that larger biases were required to
change the treatment recommendation.
This idea can be turned into a threshold analysis of the
XY contrast by replacing the originally observed data DXY
by a series of alternative values. In the analyses in the
following, we explore 20 alternative values, in which
D
Adj
XY5DXY6k  step; k51; 2:::10. For example, the orig-
inal mean weight change difference between Low Carb and
No diet is 9.34. Accordingly, we rerun the analysis with 20
alternative values ranging from 4.34 to 14.34 in ‘‘steps’’ of
0.5 kg. The process is repeated for each of the pairwise con-
trasts on which direct evidence exists. Where the threshold
is less than or equal to the step size of 0.5 kg, we specified a
finer grained analysis with steps of 0.1 kg. For the osteopo-
rosis data set where treatment effects are expressed as log
odds ratios (LORs), steps of 0.5 are used initially, followed
by steps of 0.1 for detailed analysis.
In each analysis, we record the goodness of fit and the
new treatment T with the highest posterior mean treatment
effect. In a well-fitting model, the standardized posterior
mean residual deviance, D, should approximate the number
of data points. This allows us to see whether the potential
bias we are considering in each contrast is compatible with
the rest of the evidence in the network. We assume that the
bias is ‘‘known’’ with no uncertainty s2B50 (see Section 4).
OpenBUGS program code for the threshold analysis is
available in the Supplementary Materials (Section 2)/
Appendix.
3. Results
In this section, we first present the results from the
GRADE NMA analyses, then the recommended treatment
from the base-case two-stage NMA. This is followed by
the threshold analysis and finally a relation between the
GRADE NMA and threshold results.
The GRADE NMA summaries are reported in Tables 2
and 3. For the weight-loss network, overall confidence in
the NMA summary effect estimates was rated as low for four
comparisons and as moderate confidence for the remaining
six comparisons. For the osteoporosis network, overall con-
fidence in NMA summary effect estimates was rated as low
for six, moderate for nine, and high for one comparison.
The results of the base-case two-stage NMA are summa-
rized in Table 4. For the weight-loss network (Table 4), re-
sults suggest that a low fat weight-loss program would be
preferred with the largest mean weight loss (7.88 kg)
compared to No diet at 12-month follow-up. The fit of
the baseline two-stage model was 11.3 compared to 10 data
points, suggesting a reasonable fit of the model to the data.
The two-stage base-case analysis of the osteoporosis
data (Table 4) suggests that risedronate results in the largest
effect (Ln OR 1.12; standard error 0.35). Teriparatide is
the second best (Ln OR  0.87). We note that the other bi-
sphosphonates (zoledronate, ibandronate, and alendronate),
as well as denosumab, are all approximately equally effec-
tive (compared to placebo), and all have effects that are
very similar to teriparatide. The fit of the baseline two-
stage model was 15.3 compared to 16 data points, suggest-
ing a good fit of the model to the data.
The results of the threshold analysis for the weight-loss
network (Table 5) indicate that in 6 of the 10 contrasts,
biases as large as 5 kg in either direction would make no
difference to the treatment decision. In the remaining four
cases, the conclusions are sensitive to potential bias. In
one case, Low Carb vs. LEARN, it would be necessary to
subtract 4.5 kg from the observed treatment effect to
change the decision. This amount would probably be re-
garded as representing an implausibly large bias
(þ4.5 kg) in the available evidence, and even if this was
not the case, the model fit statistic, 20.4 compared to 10
data points, indicates that such a bias adjustment would
be incompatible with the remaining evidence. The GRADE
judgment of confidence in this estimate was rated as
‘‘low’’dmeaning that ‘‘further research is very likely to
have an important impact on our confidence in the estimate
of effect and is likely to change the estimate’’ (see Table 1).
The base-case Low Fat decision could be changed to a
Low Carb decision if the estimate of the Low Carb vs. Mod-
erate difference (1.07) was raised by an additional kilo
(downward bias, 1 kg). Positive biases (þ0.9 kg) in the
Table 4. Base-case NMA based on the two-stage method, posterior
summaries
Treatment Pr(Best)
Treatment effect
estimate SD
Branded weight-loss programs
No diet 0 Reference d
LEARN 0.01 5.56 1.16
Moderate 0 6.09 0.72
Low Carb 0.17 7.49 0.72
Low Fat 0.82 7.88 0.76
Hip fracture treatments in osteoporosis
Placebo 0.00 Reference d
Teriparatide 0.32 0.87 0.72
Denosumab 0.04 0.69 0.26
Raloxifene 0.00 0.15 0.13
Zoledronate 0.02 0.68 0.17
Risedronate 0.45 L1.12 0.35
Ibandronate 0.12 0.72 0.42
Alendronate 0.05 0.75 0.21
Vitamin D 0.00 0.04 0.15
Vitamin D þ calcium 0.00 0.18 0.07
Calcium 0.00 0.02 0.17
Abbreviations: NMA, network meta-analysis; SD, standard devia-
tion.
The entries in bold indicate the treatment, which would be recom-
mended on the base-case analysis, and is the one with the highest
ranked mean treatment effect.
The treatment effect estimate for the branded weight loss pro-
grams is mean kg difference. For Hip fracture it is the odds ratio.
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Low Fat vs. Moderate, or Low Far vs. Low Carb, would also
lead to a change from the baseline Low Fat treatment deci-
sion to a bias-adjusted Low Carb decision. Assuming either
of these two biases is present generates worse fitting models
but not to an extent that rules them out on statistical grounds.
The results of the threshold analysis for osteoporosis
(Table 6) indicate that in 6 of the 16 contrasts, biases as
large as or larger than 2.5 in either direction on the log odds
scale would make no difference to the treatment decision
(risedronate). In further four cases, the conclusions are
sensitive to a potential bias between 0.9 and 2.5, but these
would still be regarded as an implausibly high level of bias
on this scale.
For further six contrasts, the baseline treatment decision
would be changed in the presence of a smaller positive bias
of 60.5 (on log odds scale). It is interesting to note that all
are relative to VitD þ calcium, and five of the six contrasts
form spurs to the main network. The residual deviance sta-
tistics suggest that a potential bias of þ0.5 for each of these
contrasts is compatible with the rest of the data.
Table 5. Threshold analysis for branded weight-loss programs [14] new recommended treatment, threshold at which new recommendation is made,
and posterior residual mean deviance of the adjusted data NMA model at the threshold adjustment
Treatment B (active)
Treatment A
(control)
Estimate
(B relative to A) SE Trials Recommendation
Bias
threshold, kg Deviance
GRADE
NMA
LEARN No diet 3.67 3.85 2 n.c n.f d Low
Moderate No diet 4.84 1.03 7 n.c n.f d Moderate
Low Carb No diet 9.34 1.04 1 n.c n.f d Moderate
Low fat No diet 5.97 2.02 3 n.c n.f d Moderate
Moderate LEARN 0.21 2.47 2 n.c n.f d Low
Low Carb LEARN 1.23 1.25 2 LEARN 4.5 20.4 Low
Low fat LEARN 4.00 2.15 2 n.c n.f d Low
Low Carb Moderate 1.07 0.46 10 Low Carb L1.0 9.9 Moderate
Low fat Moderate 1.84 0.45 4 Low Carb D0.9 12.1 Moderate
Low fat Low Carb 0.33 0.61 4 Low Carb D0.9 13.0 Moderate
Abbreviations: NMA, network meta-analysis; SE, standard error; GRADE, Grading of Recommendations Assessment, Development and Evalu-
ation; n.c., no change; n.f., not found.
Original treatment decision based on two-stage NMA was Low Fat. Entries in bold indicate evidence sources in which a plausible bias could
change the treatment decision from Low Fat. For example, if the pairwise evidence Low Carb vs. Moderate was subject to a bias of 1 kg or more
(i.e., the unbiased estimate was not the observed 1.07 kg, but 2.07 kg or higher), the treatment recommendation would change to Low Carb. n.c.
indicates no change in recommended treatment. n.f. indicates that no threshold was found within 65 kg. The GRADE assessment is from the last
column in Table 2.
Table 6. Threshold analysis for drug treatments to prevent osteoporotic hip fractures [8,15]: new recommended treatment, threshold at which new
recommendation is made and posterior residual mean deviance of the adjusted data NMA model at the threshold adjustment
Treatment B (active)
Treatment A
(control)
LOR
SE Trials Recommendation
Bias
threshold (LOR) Deviance
GRADE
NMA
B relative
to A
Raloxifene Placebo 0.17 0.24 1 Raloxifene 1.5 41.0 Moderate
Risedronate Placebo 1.77 0.24 2 Teriparatide D0.9 13.8 Low
Vitamin D Placebo 0.22 0.69 9 Vitamin D 3 92.1 Low
Vitamin D þ calcium Placebo 0.19 0.04 8 Teriparatide 1 39.0 Moderate
Vitamin D þ calcium Teriparatide 0.69 2.30 1 Teriparatide D0.3 15.3 Low
Vitamin D þ calcium Denosumab 0.51 0.99 1 Denosumab D0.5 15.3 Moderate
Alendronate Raloxifene 0.71 2.52 1 n.c n.f d Moderate
Vitamin D þ calcium Raloxifene 0.13 0.60 2 Raloxifene þ4.5 196.0 Moderate
Vitamin D þ calcium Zoledronate 0.49 0.74 2 Zoledronate D0.5 15.3 High
Vitamin D þ calcium Risedronate 0.65 1.51 3 Teriperatide L0.4 16.9 Low
Vitamin D þ calcium Ibandronate 0.54 1.42 1 Ibandronate D0.4 15.3 Low
Vitamin D Alendronate 1.31 2.36 1 Alendronate þ3.5 58.0 Moderate
Vitamin D þ calcium Alendronate 0.46 0.88 7 Alendronate D0.5 14.0 Moderate
Calcium Alendronate 1.52 4.10 1 n.c n.f d Moderate
Vitamin D þ calcium Vitamin D 0.03 0.53 2 Vitamin D þ2.5 115.2 Low
Calcium Vitamin D þ calcium 0.19 0.54 4 Calcium 1.5 18.5 Moderate
Abbreviations: LOR, log odds ratio; SE, standard error; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NMA,
network meta-analysis; n.c., no change; n.f., not found.
Original treatment decision based on two-stage analysis was risedronate. Entries in bold indicate evidence sources in which a plausible bias
could change the treatment decision from risedronate. For example, consider the pairwise (direct) evidence on placebo vs. risedronate, if the pair-
wise evidence was subject to a bias of þ0.9 on the log odds ratio scale or more (i.e., the unbiased estimate was not the observed 1.77, but was
0.87 or higher), the treatment recommendation would change to teriparatide. The GRADE NMA assessment is from the last column in Table 3.
n.c. indicates no change in recommended treatment. n.f. indicates no threshold was found within 65 on a log odds ratio scale.
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Finally, the relationship between the GRADE NMA as-
sessments and the threshold values at which recommenda-
tions would change is set out in Table 7. For this purpose,
we have considered 1 kg the largest absolute bias that
would be plausible in the weight-loss data, and 0.5 on the
LOR scale as the largest plausible bias in the osteoporosis
data set. Based on these benchmark values, which are dis-
cussed further in the following, we find no apparent rela-
tionship between the GRADE quality assessments of
NMA estimates of each contrast, and the degree to which
the treatment recommendation is sensitive to bias. The re-
sults in Tables 5 and 6 can be used to construct other bench-
marks, but this does not change our conclusions.
4. Discussion
In this article, we have set out the principles of using a
threshold analysis and illustrate its potential for examining
the reliability of conclusions from an NMA. In effect, the
threshold analysis illustrates a form of bias correction
[18,19,21], in which the decision maker asks, ‘‘how big
must the bias be in this estimate, and in which direction,
before it would lead me to change my decision? And what
would the new recommendation be?’’ In the weight-loss
example, the base-case analysis identified Low Fat as the
treatment with the highest estimated effect, but it also
showed that Low Carb ran a close second. The threshold
analysis revealed that assumptions regarding potential bias
in the most influential evidence items for the Low Fat vs.
Low Carb contrast (i.e., its direct comparison and the indi-
rect comparison via Moderate diet) were the ones where
bias could impact on conclusions. Although this may not
be surprising, what a threshold analysis adds is a quantifi-
cation of how large a bias would need to be before a deci-
sion was changed.
The follow-up question ‘‘are biases of such a size and in
such a direction plausible?’’ should then be answered by
those with knowledge of the clinical area, and with refer-
ence to the meta-epidemiological literature on bias in trials
[23,24]. For example, in the osteoporosis network, LOR
biases of 0.5 (OR 1.65) in 6 of the 16 direct estimates
would change recommendations. However, application of
such a high cutoff might be considered quite conservative.
Hip fracture is an objectively assessable outcome and the
extent of bias attributable to markers such as allocation
concealment and lack of blinding has been reported to be
well below that level [25]. We expect investigators would
be more interested in the three direct estimates where a
slightly lower level of bias (0.4, OR 5 1.49), or even the
single estimate where a bias of 0.3 (OR 5 1.35), would
be enough to change the recommendation. In two of these
three, teriparatide would be the new choice, ibandronate in
the other case. However, such biases are larger than those
previously observed in meta-epidemiological studies for
objective outcomes.
Judgments regarding bias are, of course, also subject to
uncertainty regarding the size of the expected bias [26]. A
comprehensive analysis of bias would, therefore, involve
not only a shift in the expected effect, but a concurrent
‘‘down-weighting’’ of evidence and consequent increase in
variance. The threshold values in Tables 5 and 6 should
therefore be considered conservative; in that if we had incor-
porated uncertainty, it would have had the effect of
increasing the degree of bias required to change the decision.
The implications of threshold analysis for decision
makers are different from those generated by a GRADE
assessment. The interpretation of a ‘‘low’’ confidence rating
in GRADE is that ‘‘Further research is very likely to have
an important impact on our confidence in the estimate of ef-
fect and is likely to change the estimate,’’ whereas a ‘‘mod-
erate’’ rating suggests that ‘‘Further research is likely to
have an important impact on our confidence in the estimate
of effect and may change the estimate’’ [6]. If changing an
estimate can be considered to translate into changing a de-
cision, then one might say that threshold analysis delivers a
conclusion that is diametrically opposite to GRADE
because bias in the ‘‘low’’ confidence evidence appears to
have had no consistent impact on the decision in our exam-
ples. This may not be surprising because the evaluation of
‘‘quality’’ in GRADE NMA is, in essence, a qualitative
assessment of individual pairwise contrasts and does not
take account of the overall, quantitative information flow
across networks of evidence.
A limitation of our analysis is our reliance on summary
data on each contrast, rather than the results of individual
trials. However, by starting from exactly the same data
set as the GRADE analysis, the 10 pairwise summaries
for the weight-loss data and the 16 published pairwise sum-
maries for the osteoporosis data, we have ensured a fair
comparison between the threshold-based approach and
GRADE for NMA. A better solution would be to run a
threshold analysis within a ‘‘one-stage’’ framework, prefer-
ably starting from the Bayesian posterior distributions. This
is because the two-stage analyses we have provided do not
generate quite the same results as a one-stage NMA model.
There are a number of reasons for this: some of the pairwise
summaries are from fixed-effect and others from random-
effects meta-analyses, whereas a one-stage NMA starting
from the individual trials represents a single coherent
Table 7. Relationship between distribution of GRADE NMA quality
assessments and the contrasts to which recommendations are
sensitive
Example dataset High Moderate Low Very low Total
Weight loss
All contrasts 0 6 4 0 10
Sensitive contrasts 0 3 0 0 3
Osteoporosis
All contrasts 1 9 6 0 16
Sensitive contrasts 1 2 4 0 7
Abbreviations: GRADE, Grading of Recommendations Assessment,
Development and Evaluation; NMA, network meta-analysis.
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analysis with a single random-effects variance term. Sec-
ond, a correctly performed one-stage NMA automatically
takes account of multiarm trials, whereas this information
is lost in the pairwise contrast summaries and is not recov-
ered in our base-case analysis. Finally, where there are zero
cells in the trials, the standard pooled LOR may be quite
seriously biased toward the null effect [27] and be given
inaccurate precision. In the Supplementary Materials
(Section 3/Appendix), we set out the differences between
one- and two-stage analyses and also provide an alternative
two-stage analysis of the osteoporosis data in which we use
an inconsistency model [26] to stabilize between-trials var-
iances and to maintain the correct covariance relationships
for multiarm trials. The results (Table S2/Appendix at
www.jclinepi.com) suggest that, with these improvements,
a two-stage analysis delivers base-case results that are
almost identical to a one-stage NMA.
A further weakness of our analysis, but one which
equally applies to the GRADE approach, is that each pair-
wise comparison and the potential biases attached to it are
considered independent of all the others. For example, if we
consider the GRADE domains ‘‘study limitations’’ and
‘‘publication bias,’’ it is likely that within the entire evi-
dence ensemble, several studies will be vulnerable to pre-
cisely the same kinds of bias, operating to the same or
similar extent, and in the same direction [28e33]. We have
also only considered that a single contrast can be biased. In
practice, it is more likely that several treatment contrasts in
a network would be vulnerable to the same potential biases,
for example, if participants are unable to be blinded to a
treatment to which several others are compared. Joint
modeling of such biases would be preferable. In many
cases, perhaps especially with subjective outcomes, we sug-
gest that the base-case analysis should not be a standard
NMA, but a bias-adjusted NMA. The threshold analyses
we are proposing here could be extended further to apply
to such bias-adjustment models, although we note that this
goes beyond the intentions of the GRADE framework
which is to assess confidence in the results of meta-
analysis, rather than make adjustments to a meta-analysis.
A further possibility would be to combine a threshold
analysis and risk of bias assessment to give a reliability rat-
ing similar in spirit to GRADE but driven by sensitivity to
bias as well as the likelihood of bias. We would, however,
caution against reliability ratings as they fail to provide
nuanced recommendations for clinicians. For example,
rather than assign a rating of moderate quality evidence
to a Low Fat diet, it is more useful to recommend Low
Fat but to add that a Low Carb diet could also be confi-
dently recommended to patients who do not want to try
Low Fat. This is based on both the threshold analysis and
the fact that Low Carb was a close second in the NMA.
Both GRADE NMA and the threshold analysis allow for
an explicit and systematic approach to facilitate informed
decision making. The essential difference is that the former
provides a set of unrelated quality assessments of the
estimate for each contrast, which, in the two examples we
have examined, show no relationship to the reliability of
the treatment recommendation, when interpreted as its sensi-
tivity to bias. The threshold analysis provides the decision
maker with clear information on the extent to which a
recommendation might be vulnerable to potential biases in
the evidence. Identification of items of data to which the de-
cision is sensitive could also be used to inform future
research needs, particularly where the item is also at high
risk of bias. Further statistical work is in progress to develop
the threshold analysis so the starting point is the posterior
distribution delivered by a Bayesian one-stage NMA, as this
will allow complete flexibility in the face of the complex and
irregular forms of evidence usually encountered in practice.
It is also important to ensure that the threshold analysis can
be applied to different objective functions that decision
makers might use, such as multicriterion decision analysis
[34,35] and Net Benefit analysis [36].
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2016.07.003.
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